A Randomized Trial of Combination Anastrozole plus Gefitinib and of Combination Fulvestrant plus Gefitinib in the Treatment of Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer

INTRODUCTION: EGFR signalling pathways appear involved in endocrine therapy resistance in breast cancer. This trial estimates the antitumor efficacy and toxicity of the EGFR tyrosine kinase inhibitor gefitinib in combination with anastrozole or fulvestrant in postmenopausal hormone receptor positive...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Carlson, Robert W., O'eill, Anne, Vidaurre, Tatiana, Gomez, Henry L., Badve, Sunil S., Sledge, George W.
Формат: Artigo
Язык:Inglês
Опубликовано: 2012
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3587179/
https://ncbi.nlm.nih.gov/pubmed/22418699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-012-1997-5
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы